Newco Annias debuts with glioblastoma vaccine

Immuno-oncology newco Annias Immunotherapeutics Inc. (Chapel Hill, N.C.) debuted with IP licensed from Duke University to a clinical-stage vaccine that targets solid

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE